10 research outputs found

    Receiver operating characteristic (ROC) trade-off curve for ADC, MAI and PI-RADS.

    No full text
    <p>ADC mean (black), MAI median (dark green), MAI mean (light blue) and MAI median/mean ratio (green). MAI is compared with the ADC performance alone and with the observer´s performance according to PI-RADS<sup>™</sup> v1 (dark blue) and PI-RADS<sup>™</sup> v2 (violet). The area under the curve (AUC) is 0.64±0.057 (mean, SEM) with 95% CI 0.53–0.75 and <i>P</i> 0.02 for MAI mean, 0.63±0.058 with 95% CI 0.52–0.74 and <i>P</i> 0.02 for MAI median and 0.59±0.058 with 95% CI 0.47–0.70 and <i>P</i> 0.13 for the MAI median/mean ratio. Corresponding values for the mean ADC lesion value are AUC 0.79±0.05 with 95% CI 0.70–0.88, <i>P</i> < 0.0001. Observer´s performance for PI-RADS<sup>™</sup> v1 was AUC 0.67±0.05 with CI 0.58–0.76, <i>P</i> 0.003 and for PI-RADS<sup>™</sup> v2 AUC 0.68±0.04 with CI 0.59–0.76, P 0.002. <i>N</i> malignant/benign cores 47/57. MAI and PI-RADS (v1, v2) reveal comparable performances in malignancy detection, <i>P</i> 0.60 for MAI vs PI-RADS v1 and P 0.53 for MAI vs PI-RADS v2, chi-squared test. ADC is superior to MAI in malignancy prediction, <i>P</i> 0.04, chi-squared test.</p

    Flow of participants though the study.

    No full text
    <p>STARD diagram to demonstrate the flow of participants though the study. Downstream of the “Index test” the analysis is lesion-based due to detection of multiple lesions in some patients. PSA, Prostate Specific Antigen; CAD, Computer-Aided Detection; TP, True Positive; TN; True Negative; FP, False Positive; FN, False Negative.</p

    Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth

    No full text
    <div><p>Background</p><p>Prostate cancer (PCa) diagnosis by means of multiparametric magnetic resonance imaging (mpMRI) is a current challenge for the development of computer-aided detection (CAD) tools. An innovative CAD-software (Watson Elementary<sup>™</sup>) was proposed to achieve high sensitivity and specificity, as well as to allege a correlate to Gleason grade.</p><p>Aim/Objective</p><p>To assess the performance of Watson Elementary<sup>™</sup> in automated PCa diagnosis in our hospital´s database of MRI-guided prostate biopsies.</p><p>Methods</p><p>The evaluation was retrospective for 104 lesions (47 PCa, 57 benign) from 79, 64.61±6.64 year old patients using 3T T2-weighted imaging, Apparent Diffusion Coefficient (ADC) maps and dynamic contrast enhancement series. Watson Elementary<sup>™</sup> utilizes signal intensity, diffusion properties and kinetic profile to compute a proportional Gleason grade predictor, termed Malignancy Attention Index (MAI). The analysis focused on (i) the CAD sensitivity and specificity to classify suspect lesions and (ii) the MAI correlation with the histopathological ground truth.</p><p>Results</p><p>The software revealed a sensitivity of 46.80% for PCa classification. The specificity for PCa was found to be 75.43% with a positive predictive value of 61.11%, a negative predictive value of 63.23% and a false discovery rate of 38.89%. CAD classified PCa and benign lesions with equal probability (<i>P</i> 0.06, <i>χ</i><sup>2</sup> test).</p><p>Accordingly, receiver operating characteristic analysis suggests a poor predictive value for MAI with an area under curve of 0.65 (<i>P</i> 0.02), which is not superior to the performance of board certified observers. Moreover, MAI revealed no significant correlation with Gleason grade (<i>P</i> 0.60, Pearson´s correlation).</p><p>Conclusion</p><p>The tested CAD software for mpMRI analysis was a weak PCa biomarker in this dataset. Targeted prostate biopsy and histology remains the gold standard for prostate cancer diagnosis.</p></div

    Automated mpMRI classification and histological ground truth.

    No full text
    <p>Target lesions were manually drawn by human observers. Sample images for (A-C) classified and (D, E) non classified PCa and benign biopsy cores. (A) Prostatitis, (B) adenocarcinoma (PCa) Gleason grade 6, (C) PCa Gleason grade 9, (D) atypical small acinar proliferation (ASAP) and (E) PCa Gleason grade 7. From left to right: (i) T2w with MAI-heatmap and outlined lesions (white line), (ii) Hematoxylin-Eosin histopathology of the corresponding biopsy cores and (iii) MAI histograms. Warm colors in MAI heatmaps (i) represent higher values in a scale 0–1. Classified lesions revealed a “warm-colored” MAI-map and a left-skewed histogram.</p

    Classification of malignant and benign biopsy cores.

    No full text
    <p>(A) Proportion of classified to non classified malignant and benign lesions. From 104 mixed type cores 36 were classified, from those (classified/total) 14/57 were benign and 22/47 malignant. (B) The classification was independent of the Gleason grade, P 0.713 R 0.193 Pearson correlation (C) Classification of benign lesions. ASAP, Atypical Small Acinar Proliferation; FMD, Fibromuscular Dysplasia; BPH, Benign Prostatic Hyperplasia.</p

    CAD performance is reliable for lesions larger than 1 ml.

    No full text
    <p>(A) Counts of classified and non classified cores in relation to their volume. Volume distribution of all lesions (number, %): 0–0.5ml (51, 49.04), 0.5–1.0ml (38, 36.54) and larger than 1.0ml (15, 14.42). True positive (TP, blue) lesions include classified PCa, true negatives (TN, cyan) are the non classified benign cores, false positives (FP, yellow) are the classified benign cores and false negatives (FN, red) the non classified PCa. The CAD-sensitivity increases and the number of FN decreases towards larger lesion volumes: (sensitivity % / FNR %) 27.27/31.37 for 0–0.5ml lesions, 53.33/18.42 for 0.5–1.0ml lesions and 80.00/13.33% for lesions larger than 1.0ml. (B) MAI score with lesion volume. A strong trend for a positive correlation between lesion size and MAI-score was found for TP lesions (P 0.057, Pearson´s correlation) but not for any of the remaining categories (TN, FP and FN, P > 0.1, Pearson´s correlation). (C) Lesions smaller than 0.5 ml show the same malignancy incidence and comparable aggressiveness compared to larger lesions (Ci) Lesions smaller than 0.5 ml (number, %) benign (29, 56.86) malignant (22, 43.14), (Cii) Gleason histogram for malignant lesions smaller than 0.5 ml, (Ciii) Lesions larger than 0.5 ml (number, %) benign (28, 57.14) malignant (21, 42.86), (Civ) Gleason histogram for malignant lesions larger than 0.5 ml.</p
    corecore